// App-Quantinova.ai

1880 : Baricitinib 4 Mg and 2 Mg Once Daily Reduced Pain in Both Patients Who Were Opioid Users and Non-users in Active Rheumatoid Arthritis: A Post-hoc Analysis of Phase 3 Trials

Researchers

Presenter

  • Yvonne Lee

Principal Investigators

  • Jeffrey Curtis

  • Daojun Mo

  • Terence Rooney

  • Li Xie

  • Christina Dickson

  • Douglas Schlichting

  • Amanda Quebe

  • Anabela Cardoso

  • Lee Simon

  • Peter Taylor

Medical Centers

  • Western Univeristy, London, ON, Canada

  • Northwestern University, Feinberg School of Medicine, Chicago, IL

  • University of Alabama at Birmingham, Birmingham, AL

  • Eli Lilly and Company, Indianapolis, IN

  • SDG LLC, Cambridge, MA

  • University of Oxford, Oxford, United Kingdom

Locations

  • Canada

  • United States

  • United Kingdom

Companies

  • Eli Lilly and Compan

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • Body mass index

Drug/Treatment

  • Baricitinib

  • Epimorph

  • BARI

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved